Why Are Hoth Therapeutics Shares Moving Today?
Hoth Therapeutics Inc (NASDAQ: HOTH) announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model.
The data support the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ.
HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer's.
Hoth reports that the longer treatment before the beginning of testing improves the performance of more mice in the water maze and appears to affect anxiety-like behavior in the elevated plus maze positively.
The groups of mice treated with the higher doses, 20mg/kg and 40mg/kg of HT-ALZ, appear to have the most benefit, with the 20mg group already showing significant improvement in spatial memory in the water maze.
The elevated plus maze test is one of the most widely used tests for measuring anxiety-like behavior.
Previously Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid.
The initial data showed a significant decrease in Aβ in male and female mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.
HOTH stock was up by 16% at one point during the premarket session.
Price Action: HOTH shares are down 6.28% at $4.03 on the last check Wednesday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Why Are Hoth Therapeutics Shares Moving Today? originally appeared on Benzinga.com
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.